[Series] Strengthening nationally led approaches to new product introduction for HIV prevention

As the pipeline of new HIV prevention technologies (including long-acting injectables, vaginal rings, antibody infusions, and, potentially, vaccines) expands careful planning is needed to ensure these innovations are effectively and equitably introduced within public health systems. Such planning is particularly important because the introduction and scale-up of HIV prevention tools has historically been hampered by insufficient national ownership, implementation in pilot settings that do not reflect the realities of broader public health systems, insufficient community engagement, and fragmentation across financing, regulatory pathways, and service delivery domains.